Use of recombinant activated factor VII in Primary Postpartum Hemorrhage its necessity in supply to the peripheries
DOI:
https://doi.org/10.7439/ijbar.v4i1.933Abstract
Postpartum hemorrhage (PPH) is a life-threatening emergency in obstetrics. In some critical cases, hemostasis is hard to achieve even after a hysterectomy has been performed. Early, effective and preferably non-invasive treatments that can reduce maternal mortality and morbidity are therefore essential. Recombinant activated factor seven (rFVIIa) has been reported as a promising adjuvant therapy for obstetric hemorrhage, although it remains unlicensed for this indication. We are presenting four cases of primary PPH successfully managed using rFVIIa.Downloads
Download data is not yet available.
Downloads
Published
2013-02-01
Issue
Section
Case Report
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
How to Cite
Use of recombinant activated factor VII in Primary Postpartum Hemorrhage its necessity in supply to the peripheries. (2013). International Journal of Biomedical and Advance Research, 4(1), 64-66. https://doi.org/10.7439/ijbar.v4i1.933
